initi coverag specul buy price target
initi coverag nephro specul buy rate
price target neph commercial-stag manufactur market high-
perform water purif product hospit dialysi commerci
environment concern new water-qu regul spur high-
end filter market higher incid water born pathogen increas
case hospital-bas infect result new stricter requir
incent healthcar servic provid led facil oper deploy
higher-qu ultrafilt water system caus market
product expand near billion annual level us alon
product innov cost benefit allow nephro gain market share
larger competitor despit number larger more-entrench
competitor water filtrat market nephro outpac filter
provid offer clear advantag product includ longer filter life
fewer change-out finer membran filter technolog
recent quarterli revenu growth expect maintain momentum recent
revenu growth includ growth product revenu earlier
month compani pre-announc revenu growth includ
product revenu increas revenu growth
new product market entri also geared-up near-term rest
laurel nephro target sever new near-term product launch well
introduct product new market first expect later
year could commerci launch second-gener hemodiafiltr
use acut kidney dialysi machin follow launch
dialys regener filter system use treat acut kidney injuri
target nephro also hope enter new relat
market water pathogen diagnost test kit later year target core
hospit market all-in-al new product launch next month
forecast help compani keep annual revenu growth healthi
appeal valuat still undiscov nephro share trade
revenu well industri peer ratio despit higher expect
growth price target reflect appreci current level
expect investor becom awar nephro share begin
initi coverag
nephro commerci stage compani develop sell high perform water
purif product medic devic commerci market nephro ultrafilt use
hospit medic clinic ad protect remov bacteria virus water
thu provid barrier assist improv infect control shower sink ice
machin addit nephro ultrafilt use dialysi center assist ad
remov endotoxin biolog contamin water bicarbon
concentr suppli hemodialysi machin patient
nephro core filtrat technolog mechan pass liquid pore polysulfon
hollow fiber filter pore significantli smaller compet product result
highli effect elimin water born pathogen includ legionella bacteria caus
legionnair diseas virus elimin microbiolog filter
market addit fiber structur pore densiti hollow fiber technolog
employ compani enabl significantli higher flow rate polysulfon hollow
recent compani enter commerci market ultrafiltr product
initi focu hospit food servic facil militari outdoor recreat product
addit compani establish separ subsidiari specialti renal product inc
srp employ hemodiafiltr hdf technolog develop second gener
compani olpr hemodiafiltr system fda medic devic
enabl nephrologist provid hdf treatment patient end stage renal diseas esrd
compani found healthcar profession affili columbia univers
medic center/new york-presbyterian hospit develop commerci altern
method hemodialysi sinc found compani develop filtrat
technolog meet demand liquid purif area particular water
purif nephro maintain execut headquart research develop facil
sale market offic south orang new jersey
environment concern new water-qu regul spur
hospit market remain nephro largest market opportun particularli relat reduc
elimin grow incid healthcar associ infect hai among patient
recent studi us center diseas control found approxim
million annual patient us hospit affili clinic occurr hai mani
caus water born bacteria virus thrive age complex plumb
system often found healthcar facil
recent feder initi increas need healthcar facil reduc
occurr hai patient first afford act pass march put
place comprehens health insur reform creat incent healthcar provid
reduc expens associ repeat medic procedur longer hospit stay associ
hai recent june center clinic standard qualiti center
medicar medicaid servic announc addit requir facil
develop polici procedur inhibit growth spread legionella
opportunist pathogen water system go forward surveyor review polici
procedur report document water manag implement result verifi
facil compliant requir mani case caus healthcar facil oper
pro-act manag water system prevent infect
nephro ultrafiltr product current target follow market
hospit healthcar facil filtrat water wash drink aid
infect control filter produc water suitabl
wound cleans clean equip use medic procedur
wash surgeon hand
dialysi center filtrat water bicarbon concentr use
commerci facil filtrat purif water
ice machin soft drink
includ use
militari outdoor recreat individu water purif devic
use soldier backpack produc drink water
field well filter custom use remot water process
filtrat product use hospit clinic requir obtain us fda approv prior
dsu in-lin ultrafilt provid dual-stag
protect water born pathogen dsu primarili use
filter potabl water feed ice machin sink medic equip
endoscop washer surgic room humidifi
month product life use hospit set
ssu in-lin ultrafilt provid single-stag
protect water born pathogen ssu primarili use
filter potabl water feed sink shower medic equip
product life month use hospit set
sink shower product line includ point-of-us microfilt
provid protect water born pathogen primarili use filter potabl
water feed sink shower use patient hospit room
month product life use hospit set
hydraguard hydraguard flush cartridg
ultrafilt provid single-stag protect water born pathogen
hydraguard ultrafilt primarili use filter potabl water feed
ice machin medic equip endoscop washer
surgic room humidifi product newest entrant
nephro hospit ultrafiltr product line fda market
clearanc hydraguard receiv decemb ship
commenc juli initi ship hydraguard flush
septemb hydraguard up-to product life
hydraguard-flush product life use
hospit set shown graphic right
chart outlin potenti market opportun nephro filter approxim
hospit clinic facil need water filter site shower sink etc
per facil potenti market million filter assum typic life month per filter
replac cost per filter approxim per day equat million
potenti market annual compani ultrafilt hospit market slow
adopt new technolog budget constraint howev compani estim less
potenti hospit site use ultrafilt use nephro filter
figur market potenti nephro filter hospit
benchmark compani llc nephro
dialysi center also key market compani filter dialysi clinic dedic
water purif system place produc water bicarbon concentr two
essenti compon make dialys liquid remov wast materi blood
hemodialysi patient accord recent survey american journal kidney diseas
approxim dialysi clinic oper us estim
hemodialysi machin use per facil averag servic estim
patient annual medicar primari health payor dialysi procedur us
elig medicar reimburs dialysi center us must meet certain minimum
hospitalsnumb us filter locat per filter monthsestim replac filter per filter annual market standard agencyfdaperc market market alreadi use neph
standard set sever standard group feder agenc administ medicar
us approv stricter requir water qualiti
hospit set water filter use dialysi center locat must receiv market
clearanc us fda compani water filtrat product dialysi center market
dsu ssu ssu mini filter in-lin ultrafilt provid
protect bacteria virus endotoxin product
month product life dialysi set use revers osmosi ro filter water
bicarbon line lead dialysi machin polish filter portabl ro machin
nephro endopur cartridg ultrafilt provid single-stag protect
bacteria virus endotoxin endopur product life
dialysi set use primarili filter water larg system design provid
ultrapur water entir dialysi clinic endopur avail
configur endopur cartridge-bas plug play market entri requir
plumb instal replac endopur receiv fda market
clearanc march compani began ship product later year
endopur filter similar design compani hydraguard filter hospit
market shown
compani estim market dialysi center ultrafilt approxim million
annual us due tighter facil regul nearli us center current use
filter daili oper
largest recent market compani filtrat product commerci market
includ facil restaur food servic facil conveni store
industri locat compani line five nanoguard product includ in-lin plug-in
cartridg small pore size ultrafilt provid dual-stag retent organ
inorgan particl filter bacteria virus water
recent compani introduc aether line barrier filter
commerci market follow acquisit biocon
aether line includ four separ filter sediment carbon block scale
control carbon scale see photo right due higher requir
water volum typic use site estim
us compani believ potenti market commerci
ultrafilt million annual us penetr ultrafilt
commerci site almost howev due compani
recent entri market segment certain establish larger
competitor nephro market penetr small repres
larg opportun grow market share improv technolog
better product cost econom
nephro also market individu water treatment devic iwtd
militari outdoor recreat market compani iwtd allow
soldier field deriv drink water freshwat sourc
enabl soldier remain hydrat help maintain mission effect
unit readi extend mission reach nephro iwtd valid militari
meet nsf protocol standard also approv us armi public
command test evalu command deploy addit
agreement camelbak product llc compani also market iwtd public use
outdoor recreat
new product market entri gear near-term
rest laurel nephro also target sever new product launch near-term
well introduct product new market first expect later year
like commerci launch second-gener hemodiafiltr use acut
kidney dialysi machin follow launch dialys regener filter system use
treat acut kidney injuri target nephro also hope enter new
relat market water pathogen diagnost test kit later year target core hospit
market all-in-al new product launch next month forecast help
compani keep annual revenu growth healthi rang
current standard care unit state patient chronic renal failur
hemodialysi hd process toxin clear via diffus typic time weekli
hour per treatment patient patient acut renal failur howev current
standard care us hemofiltr hf process toxin clear via convect
hf offer much better remov larger size toxin compar hd howev hf
treatment challeng patient perform daili basi typic take
hour per treatment hemodiafiltr hdf altern dialysi modal
combin benefit hd hf singl therapi clear toxin use diffus
convect though wide use unit state hdf preval europ
perform grow number patient due reduc side effect improv surviv
rate sicker patient
nephro market olpr hemodiafiltr modul olpr md hemodiafilt
substitut filter on-lin mid-dilut hdf system enabl standard hd
machin perform hdf system conform current industri standard clear
fda market hdf system clear fda adopt hdf
us slow howev due difficulti perform procedur current work-
flow practic last four year compani work davita healthcar
partner rate renal research institut divis freseniu medic fm
rate vanderbilt univers conduct evalu nephro hdf system clinic
use feedback joint studi nephro form new subsidiari specialti renal
product develop second-gener hdf system prototyp second-gener
system develop goal easier use lower capit cost smaller space
requir reduc mainten srp separ fund seri
financ million compani target fda clearanc commerci launch
second-gener hdf system end year
srp also work develop dialys regener filter system continu renal
replac therapi crrt procedur use treat acut kidney injuri rather chronic
disease-rel kidney diseas compani estim procedur perform
approxim annual us design goal srp crrt system would
reduc cost labor mainten materi use procedur reduc treatment
time patient pend fda clearanc compani hope launch new product
first part next year diagram depict nephro dialys regener filter
benefit goal
benchmark compani llc nephro
nephro also intend enter market waterborn pathogen diagnost kit later
hospit requir test water qualiti period basi due recently-enact
regulatori requir typic involv hospit employe gener member
mainten staff obtain water sampl mani differ locat around
facil send sampl outsid lab test servic analysi data
compil nephro altern develop all-in-on do-it-yourself water test
system reduc outsid cost hospit provid faster test turn-around time
fulfil regulatori requir nephro kit come custom hard pelican case easi
portabl includ dna/rna assay tube steril sampl collect bag nephro ultrafilt
concentr sampl portabl real-tim open sourc thermocycl featur autom
composit report avail cloud use hospit employe compani intend
market kit regular hospit product distributor system
product innov benefit allow market share gain
despit number larger more-entrench competitor water filtrat market nephro
outpac filter provid offer clear advantag product includ longer
filter life fewer change-out finer membran filter technolog
nephro compet sever larger establish competitor core hospit
filtrat market includ rate pall-aquasaf product line
rate cuno product rate everpur brand compani
success market product line larger competitor sever factor
uniqu attribut product featur greater product reliabl user-friendli
product design better meet critic custom need
target specif custom group mission-crit product need
nephro pursu allianc and/or acquisit opportun joint product develop
distribut figur compar nephro filter attribut compet aquasaf
brand product pall subsidiari exampl figur show
technolog advantag nephro filter includ smaller pore size filtrat nanomet
compar nanomet longer filter life requir fewer change-out time
comprehens regulatori clearanc across entir product line
benchmark compani llc nephro
nephro also employ distributor model sale market compar larger
competitor often direct sale forc allow better custom servic
local respons support mani case nephro manag global sale market
activ new jersey headquart offic warehous major distributor
garrett-callahan chem-aqua hoh tqm singl custom account
total sale recent full year recent commerci market
entri compani also maintain small sale market function la vega nevada
former headquart biocon acquisit
recent quarterli revenu growth expect maintain momentum
recent quarterli financi result june nephro report stellar year-over-year
revenu growth includ growth product revenu earlier month
compani pre-announc revenu growth consist increas product revenu
total revenu growth
sinc complet transit new manag strateg re-focu nephro deliv
signific steadi revenu growth averag year-over-year product revenu growth
past quarter begin fuel product revenu growth new fda
product clearanc addit custom compani ultrafiltr product particularli
hospit sector
recent nephro pre-announc revenu million end septemb
approxim increas period one year ago record quarterli
perform growth expect led increas sale ultrafiltr devic
hospit well sale new biocon commerci filter product third quarter pre-
announc compani also report cash hand end period million
roughli start quarter reduct cash burn previou
period full financi result expect report nephro earli novemb
recent full quarterli report nephro report revenu million
increas year-over-year led growth nearli product revenu product revenu
year increas due higher custom count hospit sector well inclus
sale water filter hospit food servic market commerci sector follow
late purchas biocon product specif gear market
gross margin second quarter decreas primarili due
increas direct product cost revenu support increas revenu
off-set posit adjust inventori reserv gross margin show improv vi --
vi previou quarter howev exampl oper expens includ
research develop depreci amort sell gener administr
cost increas approxim million million prior year
period still less increas revenu higher oper expens year stem
new program water pathogen diagnost test system well increas
overhead support higher revenu exampl higher profession investor relat fee
increas sale market staf expens relat expans two oper
facil expens increas slightli second quarter nephro
net overal result compani slightli increas oper loss million
per share per share adjust ebitda second quarter
compani water filtrat busi factor certain overhead expens
relat new product develop specialti renal hemodiafiltr water qualiti
diagnost area improv neg neg previou year
oper cash burn nephro approxim million off-set
net proce million equiti offer complet quarter end
june compani million cash hand addit compani
approxim million combin outstand secur note payabl balanc due
revolv credit facil roughli amount start year nephro also hold
interest subsidiari specialti renal product rais million
capit develop next gener water filtrat product compani expect
benefit futur nephro recent state believ adequ
work capit last mid part next year
octob pre-announc financi result nephro announc preliminari
revenu third quarter end septemb would million revenu growth
third quarter driven increas sale ultrafiltr product new custom
particularli hospit well sale outbreak respons water pathogen prevent
product correl outbreak water born pathogen warmer summer month
compani also relat end quarter held million cash hand
would repres oper burn approxim quarter
increas revenu guidanc whole million
million previous earlier nephro manag relat expect quarterli
gross margin remain area
bear mind preliminari result recent revenu guidanc estim
nephro post revenu million year-over-year reduc net
loss pre-undeclar subsidiari dividend per share compar net
loss per share period one year ago estim third
quarter includ slightli improv gross margin compar higher
oper expens million versu million revenu growth expect accru
higher sale water filtrat product new custom includ hospit
contribut year biocon commerci water filter product line acquir late
compani expect report complet financi result quarter earli
fourth quarter whole estim nephro record revenu
million million respect increas quarter-over-quart year-
over-year net loss per share per share equival
loss period one year ago season slowdown fourth
fiscal quarter nephro particularli commerci outbreak respons sector
look ahead sever pend event expect contribut continu revenu growth
improv bottom line financi result nephro includ
launch later year new water pathogen diagnost test kit
launch also late next gener hemodiafiltr dialysi system develop
launch dialys regener filter system also srp continu renal
replac therapi market pend clearanc
estim new product launch well growth new custom
help boost nephro revenu year million includ product revenu growth
assum slightli improv gross margin well increas oper expens
approxim year-over-year million estim compani decreas
oper loss next year million per share forecast fiscal look
similar project revenu growth million allow break-even
bottom line result posit ebitda posit oper cash flow improv oper cash
flow go forward also expect help compani stretch remain cash hand
model need addit equiti debt financ nephro go
forward except perhap smaller warrant option convers
figur follow page depict compani histor project annual revenu mix
segment
benchmark compani llc nephro
turnaround complet compani set continu growth
serv compani board director sever year daron evan came board
presid ceo nephro april previous serv cfo
merg capricor therapeut capr rate posit sever
divis johnson johnson rate addit experi small
larg biotechnolog medic devic firm brought addit experi privat equiti
manag consult nephro soon daron evan join nephro andi astor
appoint cfo compani follow thirti year experi financ
oper includ presid cfo posit open sourc consult group acquir
amazon buy cover kurno experi consult insur softwar
public account publish system compani key recent hire includ shane
sullivan vice-president sale monet carnahan vice-president dialysi product group michael milman head
 vashon thoma head qualiti regulatori kimothi smith vice-president diagnost product
greg luca head
detail nephro manag team shown
daron evan presid ceo
former cfo capricor capr
past experi johnson johnson arthur littl booz allen
degre duke ms biomed engin ba chemic engin
andi astor cfo
former presid cfo open scg amazon
past experi enterprisedb asurion ernst young
degre wharton ba math clark
michael milman senior director product develop
former engin rate
year product design develop experi overal
bs mechan engin lehigh univers
formerli rate appli instrument
ba busi admin usc
professor microbiology/epidemiolog univers nevada
phd epidemiolog
industri expert area molecular genet diagnost food safeti
former founder/own biocon/aeth system acquir
former manag posit gallo wine
formerli program manag freseniu fm rate
regist nurs year nurs experi kidney diseas care
nurs degre motlow state tennesse
vashon thoma senior director qualiti regulatori affair
formerli integr dental system appli dna scienc
ms pace univers ba univers buffalo
addit daron evan chairman nephro board director compris strong line-up
execut area corpor law life scienc invest corpor financ
oper medic devic dermatolog pharmaceut technolog nephro outsid
director includ tom gwydir current chief inform offic london stock exchang
arthur amron partner wexford capit member new york bar associ dr
paul mieyal director life scienc wexford capit malcom persen current
presid resolut perform consult oliv spandow current cfo idoc
optometri member servic organ alisa lask current vice presid gener
manag galderma nestl nesn sw rate skin health compani
manufactur market product use hospit clinic set nephro
requir obtain market approv us fda well intern agenc
standard-set organ exampl c-mark design requir market
europ addit compani requir obtain input approv number
feder agenc regulatori group product market commerci militari
area date compani compil posit track record relat regulatori review
product futur growth could neg impact regulatori delay non-approv
new product develop recent posit corpor move eye toward
improv investor relat help boost neph stock consider
nephro current histor compet number larger compani core
market filtrat product expect continu futur larger
compani includ offer advantag price advertis
market due greater financi resourc exampl in-hous sale staff rather
distributor howev date compani success market filtrat product
larger competitor competit advantag improv technolog featur
lack profit
nephro histor oper profit basi forecast fiscal
year next estim compani oper cash burn
end septemb nephro held million cash manag recent state
believ adequ financi resourc last mid-next year
compani grow revenu reduc oper cash burn far year
expect continu trend immedi futur nephro may requir rais
addit capit futur may caus dilut current sharehold
trade volum neph exchang compar light share per day
share rel limit histori trade compar healthcar stock
despit recent initi increas compani exposur investor news regard
neph target market partner and/or competitor could lead signific volatil stock
still undiscov view nephro share trade revenu well industri
peer ratio despit higher expect growth
recent posit corpor move eye toward improv investor relat help boost
neph stock consider fall initi includ revers split juli up-list
nasdaq capit market august attend compani manag sever investor
confer recent month ring close bell earlier month still neph
stock current trade next year estim revenu well averag
estim revenu peer group eight medic product compani despit
consider higher revenu growth forecast neph next year versu averag
peer group
thu place price target neph share reflect potenti appreci
current trade level compani increas share price market capit well
higher recent trade volum also expect make share attract
institut investor go forward addit recent common stock equiti rais
million may million fund srp research subsidiari last fall put
compani firmer financi stand quarterli revenu growth reduc oper
cash burn far culmin posit preliminari result releas
addit number new product product line enhanc tap launch
next month believ compani well posit maintain double-digit top
line growth futur reach potenti surpass profit posit oper cash
flow well
therefor initi coverag neph share specul buy rate
price target reflect potenti share appreci time
insert metafil
benchmark compani llc nephro
fye revenu product royalti total net good gross expens research depreci sell gener chang fair valu conting total oper incom expens net loss extinguish interest interest incom expens total loss undeclar undeclar deem loss tax expens net incom incom per incom per share share ratio revenu growth margin amort non-cash
benchmark compani llc nephro
fye receiv leas net current expens total plant equip leas right-of-us leas net less intang suppli agreement total liabilitiessecur revolv credit portion secur note current total debt total total liab
benchmark compani llc nephro
fye activ net amort non-cash decreas oper asset account inventori prepaid expens oper liabil account accru expens net cash use oper activ net cash use invest activ proce common stock net proce long-term proce subsidiari stock repay long-term net cash use invest exchang decreas begin end
